Lexaria Bioscience Corp. (NASDAQ: LEXX) reported interim results from its phase 1b clinical study comparing its DehydraTECH-processed semaglutide formulation to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE